ECONOMIC BURDEN OF PSORIASIS WITH CONCURRENT OR SUBSEQUENT PSORIATIC ARTHRITIS: A RETROSPECTIVE OBSERVATIONAL STUDY IN GERMANY
Author(s)
Shun-Chiao Chang, DSc1, Belene Podmore, PhD2, Mariel Arvizu, ScD, MD1, Yiyan Liu, PhD1, Raquel López González, MSc2, Agueda Azpeitia, BSc2, Lyndsi Licona, MSc2, Dominik Obermüller, PhD3, Paul Ludwig, MSc3, Matthias Augustin, MD4.
1Takeda Development Center Americas, Inc., Cambridge, MA, USA, 2OXON Epidemiology, Madrid, Spain, 3InGef – Institute for Applied Health Research Berlin GmbH, Berlin, Germany, 4Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
1Takeda Development Center Americas, Inc., Cambridge, MA, USA, 2OXON Epidemiology, Madrid, Spain, 3InGef – Institute for Applied Health Research Berlin GmbH, Berlin, Germany, 4Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
OBJECTIVES: To quantify real-world economic burden of psoriasis (PsO), including healthcare resource utilization (HCRU), costs, and sickness leave, stratified by psoriatic arthritis (PsA) status.
METHODS: This retrospective study assessed HCRU and costs in patients enrolled in an anonymized German healthcare claims database (InGef 2015-2024). Individuals with incident PsO (index=first PsO diagnosis) and ≥12 months’ continuous enrolment pre/post-index date were categorized as PsO-only, PsO with subsequent PsA (PsA diagnosis 30 days after index), or PsO with concurrent PsA (PsA diagnosis at index). Economic burden comprised HCRU, healthcare costs, and disease-related sickness leave during follow-up.
RESULTS: The study identified 108,025 patients with PsO-only, 4429 with subsequent PsA, and 2807 with concurrent PsA; mean (SD) follow-up ranged from 4.6 (2.2) to 5.4 (2.0) years across cohorts. Patients who developed subsequent PsA were slightly younger than those with PsO-only or concurrent PsA (48.4 vs 50.4-50.6 years old). Compared with PsO-only, PsO with PsA cohorts had a higher comorbidity burden (56% vs 69-71% with Charlson Comorbidity Index score ≥1). HCRU was substantial across cohorts and consistently higher with PsA. PsO/PsA-related specialist visits were common (≥82%), while disease-related inpatient admissions were more frequent with subsequent or concurrent PsA (8% vs 26-38%). Mean all-cause total costs per patient-year were higher in PsO patients with subsequent or concurrent PsA than PsO-only (€6395-7000 vs €4232) and were primarily driven by prescription costs (€2574-€2745 vs €363). Productivity burden was greater among those with PsA compared with PsO-only, with higher PsO/PsA-related sickness leave (46.3-47.1 vs 7.7 per 1000 person-years) and longer cumulative mean duration per patient (96-104 vs 51 days).
CONCLUSIONS: PsO patients who develop PsA experience pronounced impact on HCRU, costs, and productivity than those with PsO alone, highlighting the need and value of early intervention during the PsO disease course to mitigate progression to PsA.
METHODS: This retrospective study assessed HCRU and costs in patients enrolled in an anonymized German healthcare claims database (InGef 2015-2024). Individuals with incident PsO (index=first PsO diagnosis) and ≥12 months’ continuous enrolment pre/post-index date were categorized as PsO-only, PsO with subsequent PsA (PsA diagnosis 30 days after index), or PsO with concurrent PsA (PsA diagnosis at index). Economic burden comprised HCRU, healthcare costs, and disease-related sickness leave during follow-up.
RESULTS: The study identified 108,025 patients with PsO-only, 4429 with subsequent PsA, and 2807 with concurrent PsA; mean (SD) follow-up ranged from 4.6 (2.2) to 5.4 (2.0) years across cohorts. Patients who developed subsequent PsA were slightly younger than those with PsO-only or concurrent PsA (48.4 vs 50.4-50.6 years old). Compared with PsO-only, PsO with PsA cohorts had a higher comorbidity burden (56% vs 69-71% with Charlson Comorbidity Index score ≥1). HCRU was substantial across cohorts and consistently higher with PsA. PsO/PsA-related specialist visits were common (≥82%), while disease-related inpatient admissions were more frequent with subsequent or concurrent PsA (8% vs 26-38%). Mean all-cause total costs per patient-year were higher in PsO patients with subsequent or concurrent PsA than PsO-only (€6395-7000 vs €4232) and were primarily driven by prescription costs (€2574-€2745 vs €363). Productivity burden was greater among those with PsA compared with PsO-only, with higher PsO/PsA-related sickness leave (46.3-47.1 vs 7.7 per 1000 person-years) and longer cumulative mean duration per patient (96-104 vs 51 days).
CONCLUSIONS: PsO patients who develop PsA experience pronounced impact on HCRU, costs, and productivity than those with PsO alone, highlighting the need and value of early intervention during the PsO disease course to mitigate progression to PsA.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE738
Topic
Economic Evaluation, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)